Bavarian Nordic To Take Prostvac Prostate Cancer Vaccine Into Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bavarian Nordic's attempt to reduce the risk associated with developing a cancer vaccine includes licensing a vetted therapy from the National Cancer Institute and developing it with the institute under a Cooperative Research and Development Agreement.
You may also be interested in...
Cancer Vaccine Maker Therion Is Up For Sale After Disappointing Phase III Results
Therion no longer plans to submit a BLA for its PANVAC-VF pancreatic cancer treatment.
THERION/NCI CANCER IMMUNOTHERAPEUTICS CRADA
THERION/NCI CANCER IMMUNOTHERAPEUTICS CRADA calls for Therion to "generate vaccine candidates based on live recombinant poxvirus vectors that express specific tumor-associated antigens" characterized by the National Cancer Institute, the privately held Cambridge, Mass.-based company announced Nov. 1. NCI Surgery Branch Chief Steven Rosenberg, MD/PhD, will be the agency's principal investigator for the five-year collaboration.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.